227 related articles for article (PubMed ID: 34281526)
21. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
22. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
[TBL] [Abstract][Full Text] [Related]
23. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
[TBL] [Abstract][Full Text] [Related]
24. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Mosleh M; Safaroghli-Azar A; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
[TBL] [Abstract][Full Text] [Related]
25. Panobinostat, a histone deacetylase inhibitor, rescues the angiogenic potential of endothelial colony-forming cells in moyamoya disease.
Jangra A; Choi SA; Koh EJ; Moon YJ; Wang KC; Phi JH; Lee JY; Kim SK
Childs Nerv Syst; 2019 May; 35(5):823-831. PubMed ID: 30815722
[TBL] [Abstract][Full Text] [Related]
26. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
Hazama Y; Tsujioka T; Kitanaka A; Tohyama K; Shimoya K
PLoS One; 2022; 17(7):e0271245. PubMed ID: 35802681
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat.
Afolabi LO; Bi J; Li X; Adeshakin AO; Adeshakin FO; Wu H; Yan D; Chen L; Wan X
Front Immunol; 2021; 12():701671. PubMed ID: 34531855
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Choi SA; Lee C; Kwak PA; Park CK; Wang KC; Phi JH; Lee JY; Chong S; Kim SK
Cancer Lett; 2019 Feb; 442():161-169. PubMed ID: 30367915
[TBL] [Abstract][Full Text] [Related]
30. "Proximal-type" epithelioid sarcoma, a distinctive aggressive neoplasm showing rhabdoid features. Clinicopathologic, immunohistochemical, and ultrastructural study of a series.
Guillou L; Wadden C; Coindre JM; Krausz T; Fletcher CD
Am J Surg Pathol; 1997 Feb; 21(2):130-46. PubMed ID: 9042279
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Chang TC; Matossian MD; Elliott S; Burks HE; Sabol RA; Ucar DA; Wathieu H; Zabaleta J; Del Valle L; Gill S; Martin E; Riker AI; Miele L; Bunnell BA; Burow ME; Collins-Burow BM
PLoS One; 2020; 15(10):e0226464. PubMed ID: 33035223
[TBL] [Abstract][Full Text] [Related]
32. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O
Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784
[TBL] [Abstract][Full Text] [Related]
33. Targeting HDACs in Pancreatic Neuroendocrine Tumor Models.
Schmitz RL; Weissbach J; Kleilein J; Bell J; Hüttelmaier S; Viol F; Clauditz T; Grabowski P; Laumen H; Rosendahl J; Michl P; Schrader J; Krug S
Cells; 2021 Jun; 10(6):. PubMed ID: 34204116
[TBL] [Abstract][Full Text] [Related]
34. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
35. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
36. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
37. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
38. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
39. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
